Importantly, in models (prostate cancer Myc-CaP, colon carcinoma CT26, melanoma B16-BL6, and prostate cancer TRAMP-C2) that were insensitive to anti–PD-1 (Fig. 4D; Supplementary Fig. S4B), TAK-243 treatment significantly sensitized tumors to anti–PD-1 (Fig. 4D; Supplementary Fig. S4B). This evidence concerns the gene MYC and prostate carcinoma.